Acadia Pharmaceuticals (ACAD) Income from Continuing Operations (2010 - 2026)
Acadia Pharmaceuticals' quarterly Income from Continuing Operations came in at 3700000.0 in Q1 2026, down 80.53% year-on-year from 19000000.0 in Q1 2025, and down 98.65% quarter-over-quarter from 273553000.0 in Q4 2025.
Acadia Pharmaceuticals has reported Income from Continuing Operations for 17 years, with the latest figure at 3700000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 80.53% year-over-year to 3700000.0; the trailing twelve-month figure through Mar 2026 stood at 375687000.0 (up 64.12% YoY), and the FY2025 full-year result was 391000000.0, up 72.66% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 3700000.0, down from 273553000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 273553000.0 in Q4 2025, with the low at 113056000.0 in Q1 2022.
- Average Income from Continuing Operations over 5 years is 20237058.82, with a median of 16553000.0 recorded in 2024.
- Year-over-year, Income from Continuing Operations slumped 139.74% in 2023 and jumped 2822.13% in 2024.
- Tracing ACAD's Income from Continuing Operations over 5 years: stood at 41675000.0 in 2022, then soared by 209.8% to 45758000.0 in 2023, then surged by 214.15% to 143751000.0 in 2024, then surged by 90.3% to 273553000.0 in 2025, then tumbled by 98.65% to 3700000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 3700000.0 (Q1 2026), 273553000.0 (Q4 2025), and 71779000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Acadia Pharmaceuticals | 3.69 Bn | 2.84 Bn | 243.27 Mn | 3.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.70 Mn |
| Dec 31, 2025 | 273.55 Mn |
| Sep 30, 2025 | 71.78 Mn |
| Jun 30, 2025 | 26.66 Mn |
| Mar 31, 2025 | 19.00 Mn |
| Dec 31, 2024 | 143.75 Mn |
| Sep 30, 2024 | 32.76 Mn |
| Jun 30, 2024 | 33.40 Mn |
| Mar 31, 2024 | 16.55 Mn |
| Dec 31, 2023 | 45.76 Mn |
| Sep 30, 2023 | -65.13 Mn |
| Jun 30, 2023 | 1.14 Mn |
| Mar 31, 2023 | -43.02 Mn |
| Dec 31, 2022 | -41.68 Mn |
| Sep 30, 2022 | -27.17 Mn |
| Jun 30, 2022 | -33.97 Mn |
| Mar 31, 2022 | -113.06 Mn |
| Dec 31, 2021 | -43.09 Mn |
| Sep 30, 2021 | -14.46 Mn |
| Jun 30, 2021 | -43.87 Mn |
| Mar 31, 2021 | -66.45 Mn |
| Dec 31, 2020 | -66.55 Mn |
| Sep 30, 2020 | -84.66 Mn |
| Jun 30, 2020 | -42.14 Mn |
| Mar 31, 2020 | -88.02 Mn |
| Dec 31, 2019 | -53.04 Mn |
| Sep 30, 2019 | -41.98 Mn |
| Jun 30, 2019 | -54.94 Mn |
| Mar 31, 2019 | -85.30 Mn |
| Dec 31, 2018 | -65.54 Mn |
| Sep 30, 2018 | -62.14 Mn |
| Jun 30, 2018 | -63.27 Mn |
| Mar 31, 2018 | -54.30 Mn |
| Dec 31, 2017 | -68.85 Mn |
| Sep 30, 2017 | -65.25 Mn |
| Jun 30, 2017 | -67.44 Mn |
| Mar 31, 2017 | -87.84 Mn |
| Dec 31, 2016 | -77.36 Mn |
| Sep 30, 2016 | -71.61 Mn |
| Jun 30, 2016 | -71.32 Mn |
| Mar 31, 2016 | -49.76 Mn |
| Dec 31, 2015 | 63.36 Mn |
| Sep 30, 2015 | -38.91 Mn |
| Jun 30, 2015 | -39.38 Mn |
| Mar 31, 2015 | -40.38 Mn |
| Dec 31, 2014 | 33.42 Mn |
| Sep 30, 2014 | -24.79 Mn |
| Jun 30, 2014 | -21.50 Mn |
| Mar 31, 2014 | -17.83 Mn |
| Dec 31, 2013 | 13.35 Mn |
| Sep 30, 2013 | -10.70 Mn |
| Jun 30, 2013 | -9.08 Mn |
| Mar 31, 2013 | -6.12 Mn |
| Dec 31, 2012 | -6.81 Mn |
| Sep 30, 2012 | -2.40 Mn |
| Jun 30, 2012 | -5.42 Mn |
| Mar 31, 2012 | -6.22 Mn |
| Dec 31, 2011 | -5.30 Mn |
| Sep 30, 2011 | -5.08 Mn |
| Jun 30, 2011 | -6.56 Mn |
| Mar 31, 2011 | -5.83 Mn |
| Dec 31, 2010 | 29.14 Mn |
| Sep 30, 2010 | -4.23 Mn |